Efficacy and safety of sacubitril-valsartan in Maintenance Hemodialysis patients with hypertension:A retrospective study.

ABSTRACT:

Background

Hypertension is associated with elevated mortality rates among individuals on maintenance hemodialysis (MHD). However, there is limited information regarding the efficacy and safety of sacubitril-valsartan (SV) in MHD patients suffering from hypertension. Consequently, this study aims to evaluate the efficacy and safety of SV in this specific patient population.

Methods

We retrospectively reviewed the data of MHD patients with hypertension who were receiving SV treatment at our hospital from January 1, 2023 to June 30, 2024. The SV dose ranged from 50 mg twice daily to 200 mg twice daily. Blood pressure measurements were compared at baseline and during follow-up intervals to assess therapeutic efficacy. Safety evaluations included comprehensive monitoring of treat

SUBMITTER: Jiang L 

PROVIDER: S-EPMC12410819 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature